•
Faking Data
Talks about Python, Data Science and Postgis
MH
Michelle Ho
VP Strategy and Operations at Renasant Bio
San Francisco Bay Area
Overview
Michelle Ho is currently the VP Strategy and Operations at Renasant Bio in the San Francisco Bay Area, with a background in Biomedical Engineering and a Ph.D. from Rice University. She has held various roles at 5AM Ventures and served as a Board Observer for multiple biotech companies, showcasing her leadership and expertise in the field.
Work Experience
VP Strategy and Operations
2024 - Current
Operating Principal
2023 - 2024
Senior Associate
2022 - 2022
Associate
2020 - 2021
Analyst
2018 - 2019
5AM Ventures is a venture capital firm that aims to finance seed and early-stage life sciences companies.
Board Observer
2021 - 2024
Radionetics Oncology is a pharmaceutical company that focuses on the discovery and development of novel radiotherapeutics.
Raised $82,500,000.00 from GordonMD Global Investments, 5AM Ventures, Crinetics Pharmaceuticals, DCVC Bio and Frazier Life Sciences.
Board Observer
2021 - 2024
Ensomaa is a genomic medicine company that develops on one-time in vivo treatments for immuno-oncology and other therapeutic applications.
Raised $205,000,000.00 from Delos Capital, Bioluminescence Ventures, Kite Pharma, SymBiosis LLC, Catalio Capital Management, Solasta Ventures, Qatar Investment Authority, Mirae Asset, 5AM Ventures and Alexandria Venture Investments.
Board Observer
2018 - 2024
RareCyte is a life science research and diagnostic development company focused on characterizing and isolating rare cells in the blood.
Raised $96,000,000.00 from Agilent Technologies, GKCC, Ron Seubert, The Forest Road Company, Arboretum Ventures, F-Prime Capital, HealthQuest Capital, 5AM Ventures and Sheatree Capital.
Board Observer
2020 - 2024
Board Observer
2019 - 2023
Novel drug delivery targeting – minimising healthy tissue damage.
Board Observer
2022 - 2022
Acquired by Bionano Genomics in November 2022
Purigen Biosystems' innovative products offer a truly transformative automated solution for DNA and RNA purification.
Raised $93,086,615.00 from Cota Capital, Agilent Technologies, 5AM Ventures and Roche Venture Fund.
Entrepreneurship Fellow
2016 - 2018
• Managed 2 portfolio life science startups in therapeutics (rHDL therapeutics) and medical devices (GuidaBot) • Developed pitch decks and led business development efforts, including key collaboration with leading siRNA biotech company • Performed market analysis, product-market-fit, and business model development for portfolio technologies • Initiated 2 new collaborations with NASH and rare metabolic disease experts • Awarded $325k NIH SBIR Phase I grant for development and safety/toxicity assessment of novel lipid-based nanoparticles for therapeutic siRNA delivery • Created and led monthly entrepreneurship book club • Led branding and outreach efforts for Fannin Innovation Studio
Director of Operations
2016 - 2018
• Led business development, validated value propositions via customer interviews with key opinion leaders in functional neurosurgery and shadowing laser ablation procedures • Directed prototype development of robotic MRI-compatible neurosurgical guidance device • Determined regulatory and go-to-market strategy • Awarded $225k NSF STTR Phase I grant to develop proof-of-concept 4-DoF robotic prototype • Won 1st Place Elevator Pitch at Texas A&M New Ventures Competition 2017 • Won acceptance into TMCx Medical Device Accelerator - Class 5 Cohort